Could an emerging modality provide a viable alternative to gadolinium-based contrast agents (GBCAs) in this high-risk patient population?
Carl Bjartmar, Chief Medical Officer, Ascelia Pharma
Advertisement
Articles by Carl Bjartmar, Chief Medical Officer, Ascelia Pharma
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
The Reading Room Podcast: A Closer Look at New Research on 177Lu-Edotreotide for Treating GEP-NETs
2
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
3
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
4
See the Real-World Impact of AI in Radiology
5